Does a cost-effective approach for the determination of KRAS mutations maximize the patient's benefit in a clinical setting? Reply

被引：1

作者：

Carotenuto, Pietro ^{[1
]}

Roma, Cristin ^{[1
]}

Rachiglio, Anna Maria ^{[1
]}

Normanno, Nicola

机构：

[1] INT Fdn Pascale CROM, Pharmacogenom Lab, Mercogliano, AV, Italy

来源：

PHARMACOGENOMICS | 2011年 / 12卷 / 03期

关键词：

D O I：

10.2217/PGS.11.7

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：309 / 310

页数：2

共 6 条

[1] Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases [J].

Baldus, Stephan E. ;

Schaefer, Karl-L. ;

Engers, Rainer ;

Hartleb, Dinah ;

Stoecklein, Nikolas H. ;

Gabbert, Helmut E. .

CLINICAL CANCER RESEARCH, 2010, 16 (03) :790-799

[2]

Carotenuto P, 2010, PHARMACOGENOMICS, V11, P1169, DOI [10.2217/pgs.10.86, 10.2217/PGS.10.86]

[3]

Jung A, 2009, J CLIN ONCOL, V27

[4]

Kobunai T, 2011, PHARMACOGENOMICS, V12, P307, DOI [10.2217/pgs.11.6, 10.2217/PGS.11.6]

[5] Implications for KRAS status and EGFR-targeted therapies in metastatic CRC [J].

Normanno, Nicola ;

Tejpar, Sabine ;

Morgillo, Floriana ;

De Luca, Antonella ;

Van Cutsem, Eric ;

Ciardiello, Fortunato .

NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (09) :519-527

[6] High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue [J].

Tol, Jolien ;

Dijkstra, Jeroen R. ;

Vink-Borger, Marianne E. ;

Nagtegaal, Iris D. ;

Punt, Cornelis J. A. ;

van Krieken, Johan H. J. M. ;

Ligtenberg, Marjolijn J. L. .

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2010, 14 (08) :2122-2131

← 1 →